PT - JOURNAL ARTICLE AU - Brian Mustanski AU - Rana Saber AU - Daniel T. Ryan AU - Nanette Benbow AU - Krystal Madkins AU - Christina Hayford AU - Michael E. Newcomb AU - Joshua M. Schrock AU - Lauren A. Vaught AU - Nina L. Reiser AU - Matthew P. Velez AU - Ryan Hsieh AU - Alexis R. Demonbreun AU - Richard D’Aquila AU - Elizabeth M. McNally AU - Thomas W. McDade TI - Geographic disparities in COVID-19 case rates are not reflected in seropositivity rates using a neighborhood survey in Chicago AID - 10.1101/2021.03.02.21252767 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.02.21252767 4099 - http://medrxiv.org/content/early/2021/03/05/2021.03.02.21252767.short 4100 - http://medrxiv.org/content/early/2021/03/05/2021.03.02.21252767.full AB - To date, COVID-19 case rates are disproportionately higher in Black and Latinx communities across the U.S., leading to more hospitalizations and deaths in those communities. These differences in case rates are evident in comparisons of Chicago neighborhoods with differing race/ethnicities of their residents. Disparities could be due to neighborhoods with more adverse health outcomes associated with poverty and other social determinants of health experiencing higher prevalence of SARS-CoV-2 infection or due to greater morbidity and mortality resulting from equivalent SARS-CoV-2 infection prevalence. We surveyed five pairs of adjacent ZIP codes in Chicago with disparate COVID-19 case rates for highly specific and quantitative serological evidence of any prior infection by SARS-CoV-2 to compare with their disparate COVID-19 case rates. Dried blood spot samples were self-collected at home by internet-recruited participants in summer 2020, shortly after Chicago’s first wave of the COVID-19 pandemic. Pairs of neighboring ZIP codes with very different COVID-19 case rates had similar seropositivity rates for anti-SARS-CoV-2 receptor binding domain IgG antibodies. Overall, these findings of comparable exposure to SARS-CoV-2 across neighborhoods with very disparate COVID-19 case rates are consistent with social determinants of health, and the comorbidities related to them, driving differences in COVID-19 rates across neighborhoods.Competing Interest StatementDr. McDade reports that he has a financial interest in EnMed Microanalytics, a company that conducts lab tests using DBS samples. Dr. D'Aquila reports personal fees from Abbvie, outside the submitted work. Dr. McNally reports personal fees from Amgen, personal fees from AstraZeneca, personal fees from Cytokinetics, personal fees from Pfizer, personal fees from Tenaya Therapeutics, personal fees from 4D Molecular Therapeutics, outside the submitted work.Funding StatementThis material is based upon work supported by the National Science Foundation under Grant No. 2035114. Additional support was provided by the Northwestern University Office of Research, the Northwestern University Clinical and Translational Sciences Institute (NIH UL1TR001422), and a generous gift from Dr. Andrew Senyei and Noni Senyei. The funding sources had no role in the study design, data collection, analysis, interpretation, or writing of the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All samples were de-identified and all research activities were implemented under protocols approved by the institutional review board at Northwestern University (#STU00212457 and #STU00212472).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon request from the corresponding author subject to an approved data sharing agreement to protect participant confidentiality.